Lynx1 Capital Management
Lynx1 Capital Management reported 31 stocks worth $646M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are GHRS (48.2%), CGEM (21.3%) and STOK (15.7%). Compared with Q2 2026, the fund opened new positions in KZIA, SRZN and YARW, added to CCCC, DTIL and KRRO, trimmed STOK and AGIO and sold out of CGON.
Latest filing: what Lynx1 Capital Management did in Q3 2026
vs Q2 2026
CGON$2.2M- Vyne Therapeutics $1.1M
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() GHRS GH Research PLC | $311M | 48.2% | 13.3M | No change | 8 of 8 | |
| 2 | ![]() CGEM Cullinan Therapeutics Inc | $138M | 21.3% | 9M | No change | 8 of 8 | |
| 3 | ![]() STOK Stoke Therapeutics Inc | $101M | 15.7% | 3.9M | −142K (−4%) | 8 of 8 | |
| 4 | ![]() CCCC C4 Therapeutics Inc | $25.1M | 3.9% | 7.5M | +204K (+3%) | 8 of 8 | |
| 5 | ![]() DTIL Precision Biosciences Inc | $17.3M | 2.7% | 2.8M | +1.8M (+190%) | 8 of 8 | |
| 6 | ![]() AGIO Agios Pharmaceuticals Inc | $15.7M | 2.4% | 473K | −2.9M (−86%) | 4 of 8 | |
| 7 | ![]() KRRO Korro Bio Inc Com | $15.3M | 2.4% | 1.5M | +6,684 (+0%) | 4 of 8 | |
| 8 | ![]() NEUP Neuphoria Therapeutics Inc | $3.1M | 0.5% | 875K | No change | 7 of 8 | |
| 9 | ![]() PASG Passage Bio Inc | $3M | 0.5% | 674K | No change | 5 of 8 | |
| 10 | ![]() PRQR Proqr Thrapeutics N V | $2.6M | 0.4% | 1.6M | +1M (+200%) | 4 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() CGON CG Oncology Inc | $2.2M | 31K |
VYNE THERAPEUTICS INC C | $1.1M | 1.6M |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Lynx1 Capital Management 13F FAQ
What does Lynx1 Capital Management own?
Lynx1 Capital Management reported 31 stocks worth $646M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are GHRS (48.2%), CGEM (21.3%) and STOK (15.7%). The table above lists every position in the filing (the top 10 without an account).
What did Lynx1 Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 6 new positions, 6 added to, 2 trimmed and 2 sold out. New positions include KZIA, SRZN and YARW. It sold all of CGON.
When will Lynx1 Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Lynx1 Capital Management's portfolio worth?
The Q3 2026 filing reports $646M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.
















